A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis

PHASE3CompletedINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

March 28, 2019

Primary Completion Date

December 8, 2021

Study Completion Date

February 14, 2022

Conditions
Psoriatic Arthritis
Interventions
DRUG

Bimekizumab

Subjects will receive bimekizumab at pre-specified time-points.

OTHER

Placebo

Subjects will receive placebo at pre-specified time-points.

Trial Locations (92)

10003

Pa0011 50011, New York

11201

Pa0011 50010, Brooklyn

14642

Pa0011 50034, Rochester

16635

Pa0011 50020, Duncansville

19104

Pa0011 50064, Philadelphia

19610

Pa0011 50006, Wyomissing

20902

Pa0011 50026, Wheaton

21740

Pa0011 50015, Hagerstown

25801

Pa0011 50050, Beckley

28144

Pa0011 50031, Salisbury

28210

Pa0011 50125, Charlotte

29486

Pa0011 50021, Summerville

30342

Pa0011 50039, Atlanta

33613

Pa0011 50037, Tampa

34684

Pa0011 50033, Palm Harbor

38305

Pa0011 50001, Jackson

40504

Pa0011 50028, Lexington

45377

Pa0011 50040, Vandalia

48911

Pa0011 50019, Lansing

63141

Pa0011 50016, St Louis

70836

Pa0011 50023, Baton Rouge

75150

Pa0011 50036, Mesquite

76710

Pa0011 50009, Waco

78731

Pa0011 50002, Austin

83702

Pa0011 50024, Boise

85037

Pa0011 50017, Phoenix

87102

Pa0011 50029, Albuquerque

92128

Pa0011 50035, San Diego

92780

Pa0011 50004, Tustin

02115-5817

Pa0011 50047, Boston

07728

Pa0011 50005, Freehold

02919

Pa0011 50008, Johnston

38119-5214

Pa0011 50012, Memphis

Unknown

Pa0011 30005, Camberwell

Pa0011 30007, Victoria Park

Pa0011 30006, Woodville South

Pa0011 50042, Rimouski

Pa0011 50043, Sydney

Pa0011 50044, Trois-Rivières

Pa0011 40009, Pardubice

Pa0011 40063, Prague

Pa0011 40066, Prague

Pa0011 40012, Zlín

Pa0011 40076, Cottbus

Pa0011 40023, Erlangen

Pa0011 40117, Frankfurt

Pa0011 40029, Hamburg

Pa0011 40071, Hamburg

Pa0011 40078, Leipzig

Pa0011 40026, Ratingen

Pa0011 40083, Budapest

Pa0011 40079, Szentes

Pa0011 40084, Catania

Pa0011 40087, Milan

Pa0011 40086, Reggio Emilia

Pa0011 20030, Chūōku

Pa0011 20043, Itabashi-ku

Pa0011 20036, Kawachi-Nagano

Pa0011 20045, Kita-gun

Pa0011 20049, Kitakyushu

Pa0011 20044, Minatoku

Pa0011 20041, Osaka

Pa0011 20046, Osaka

Pa0011 20031, Sapporo

Pa0011 20042, Sasebo

Pa0011 20032, Suita

Pa0011 40119, Bydgoszcz

Pa0011 40038, Elblag

Pa0011 40037, Lublin

Pa0011 40091, Nowa Sól

Pa0011 40044, Poznan

Pa0011 40090, Poznan

Pa0011 40118, Torun

Pa0011 40041, Warsaw

Pa0011 40097, Warsaw

Pa0011 40098, Warsaw

Pa0011 40039, Wroclaw

Pa0011 40043, Wroclaw

Pa0011 20005, Korolyov

Pa0011 20010, Moscow

Pa0011 20013, Petrozavodsk

Pa0011 20001, Saint Petersburg

Pa0011 20004, Saint Petersburg

Pa0011 20009, Saint Petersburg

Pa0011 20007, Saratov

Pa0011 20014, Ulyanovsk

Pa0011 20006, Vladimir

Pa0011 20008, Yaroslavl

Pa0011 20015, Yaroslavl

Pa0011 40111, Bradford

Pa0011 40109, Oxford

Pa0011 40116, Stamford

All Listed Sponsors
lead

UCB Biopharma SRL

INDUSTRY

NCT03896581 - A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis | Biotech Hunter | Biotech Hunter